Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis.

IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis.

Cystic fibrosis, Pseudomonas aeruginosa, and selective decontamination.

Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment.

The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis.

Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis.

Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum.

Interactions between Neutrophils and Pseudomonas aeruginosa in Cystic Fibrosis.

Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management.

Phenotypic conversion of Pseudomonas aeruginosa in cystic fibrosis.

Extrapulmonary sites of Pseudomonas aeruginosa in adults with cystic fibrosis.

TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.

Molecular identification of Pseudomonas aeruginosa recovered from cystic fibrosis patients.

Antibodies against the cystic fibrosis transmembrane regulator.

Bacteriophage Delivery by Nebulization and Efficacy Against Phenotypically Diverse Pseudomonas aeruginosa from Cystic Fibrosis Patients.

Adherence of Pseudomonas aeruginosa to cystic fibrosis buccal epithelial cells.

Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients.

Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients.

Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay.

Assessment of IgG antibodies to Pseudomonas aeruginosa in patients with cystic fibrosis by an enzyme-linked immunosorbent assay (ELISA).

Phagocytic and signaling innate immune receptors: are they dysregulated in cystic fibrosis in the fight against Pseudomonas aeruginosa?

Genetic relatedness and host specificity of Pseudomonas aeruginosa isolates from cystic fibrosis and non-cystic fibrosis patients.

Molecular identification and genotyping of Pseudomonas aeruginosa isolated from cystic fibrosis and non-cystic fibrosis patients with bronchiectasis.

In vitro activity of colistin against biofilm by Pseudomonas aeruginosa is significantly improved under "cystic fibrosis-like" physicochemical conditions.

Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis: correlation to disease, subclass distribution, and experimental protective capacity.

Suggest Documents

IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis.

Cystic fibrosis, Pseudomonas aeruginosa, and selective decontamination.

Predictive values of antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis one year after early eradication treatment.

The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis.

Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis.

Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum.

Interactions between Neutrophils and Pseudomonas aeruginosa in Cystic Fibrosis.

Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management.

Phenotypic conversion of Pseudomonas aeruginosa in cystic fibrosis.

Extrapulmonary sites of Pseudomonas aeruginosa in adults with cystic fibrosis.

TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.

Molecular identification of Pseudomonas aeruginosa recovered from cystic fibrosis patients.

Antibodies against the cystic fibrosis transmembrane regulator.

Bacteriophage Delivery by Nebulization and Efficacy Against Phenotypically Diverse Pseudomonas aeruginosa from Cystic Fibrosis Patients.

Adherence of Pseudomonas aeruginosa to cystic fibrosis buccal epithelial cells.

Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients.

Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients.

Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay.

Assessment of IgG antibodies to Pseudomonas aeruginosa in patients with cystic fibrosis by an enzyme-linked immunosorbent assay (ELISA).

Phagocytic and signaling innate immune receptors: are they dysregulated in cystic fibrosis in the fight against Pseudomonas aeruginosa?

Genetic relatedness and host specificity of Pseudomonas aeruginosa isolates from cystic fibrosis and non-cystic fibrosis patients.

Molecular identification and genotyping of Pseudomonas aeruginosa isolated from cystic fibrosis and non-cystic fibrosis patients with bronchiectasis.

In vitro activity of colistin against biofilm by Pseudomonas aeruginosa is significantly improved under "cystic fibrosis-like" physicochemical conditions.

Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis: correlation to disease, subclass distribution, and experimental protective capacity.

Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis.

Recommend Documents

Follow Us